Mr. Justin Hanka reports

MINDBIO ANNOUNCES UPSIZE TO PRIVATE PLACEMENT UP TO $1.5 MILLION

Mindbio Therapeutics Corp. is upsizing its non-brokered private placement previously announced on Feb. 18, 2026, from $650,000 to up to $1.5-million, pursuant to which the company intends to now issue up to 2.5 million units of the company at a price of 60 cents per unit for gross proceeds of up to $1.5-million. Each unit will consist of one common share of the company and one share purchase warrant. Each warrant will entitle the holder to acquire an additional share at a price of 80 cents for a period of 36 months following closing of the offering, subject to accelerated expiry in the event the closing price of the shares on the Canadian Securities Exchange exceeds $1.00 for 10 consecutive trading days.

In connection with completion of the offering, the company will pay finders' fees to eligible third parties who have introduced subscribers to the offering. All securities issued in connection with the offering will be subject to restrictions on resale for a period of four months and one day in accordance with applicable securities laws.

Completion of the offering remains subject to final board and regulatory approvals.

About Mindbio Therapeutics Corp.

Mindbio is a biotechnology company that is commercializing AI (artificial intelligence) prediction technologies for drug and alcohol intoxication detection via voice analysis. The AI prediction model uses over 50 million data points to predict alcohol intoxication with remarkable accuracy, just by using the human voice. The company is developing an enterprise platform including Edge-AI kiosks integrating bespoke hardware and software for the detection of drug and alcohol intoxication using the human voice and AI in a range of enterprise environments including the mining industry, aviation, construction and law enforcement.

We seek Safe Harbor.